PubMed Health⌕ Search

Biomedical subjects

B Jackson

Publications and source records attributed to B Jackson.

At least 235 records · Page 13Linked to original sources
PubMed1985

Renal artery digital-subtraction angiography. An outpatient investigation for renovascular hypertension.

The adequacy and convenience of the digital-subtraction angiographic procedure by means of a Diasonics DF100 as an investigation in renovascular disease were assessed over a nine-month period in 82 sequential renal artery studies, of which 76 were carried out in patients referred for the investigation of hypertension. Contrast medium was injected as a bolus by way of a centrally placed venous catheter, or a small (5 French size or smaller) arterial catheter. Patients tolerated the procedure well, and were fully mobile within 10 minutes to one hour (venous injection) and within two hours (arterial injection) after the procedure. Of the 82 studies, nine were judged as inadequate. All technical failures occurred with the venous injection technique. Of the 76 patients with hypertension, the main renal artery was judged as normal in 61. Renal artery lesions were demonstrated in 15 studies (13 patients). Renal vein renin studies, and the clinical or postoperative course supported the diagnosis of renovascular hypertension in 11 of these. Digital-subtraction angiography of the renal artery is a useful investigation in suspected renovascular hypertension. Its major advantage over conventional angiography is that it can be performed on an outpatient basis.

Adolescent↗
PubMed1985

Progesterone secreting Sertoli cell tumor of the ovary.

A 33-year-old woman presenting with secondary amenorrhea and galactorrhea was found to have a Sertoli cell tumor of the ovary. The neoplasm also had a sex cord tumor with annular tubules (SCTAT) component. Further investigations revealed that in many respects the patient was endocrinologically pregnant. She had markedly elevated serum estrogen and progesterone levels and the endometrium demonstrated pronounced decidualization, but there was no evidence of actual pregnancy. Estrogen and progesterone were demonstrated by immunohistochemistry to be present in both the Sertoli cell and SCTAT portions of the tumor.

Adult↗
PubMed1985

Enalapril (MK421) activation in man: importance of liver status.

The in vitro conversion of enalapril (MK421) to enalaprilic acid (MK422) in human autopsy tissues was examined. MK422 was measured by radioimmunoassay. Human cadaver liver was the only tissue in which significant conversion was demonstrated. The esterase activity was stable after post mortem. Autopsy liver tissues from patients with elevated ante mortem liver function tests were found to have a reduced rate of deesterification.

Angiotensin-Converting Enzyme Inhibitors↗
PubMed1985

Controlled trial of enalapril in congestive cardiac failure.

Twenty five patients with chronic congestive cardiac failure had enalapril (n = 13) or placebo (n = 12) added to their existing regimen of digoxin and frusemide in a randomised double blind trial. Four hours after the first 5 mg dose, the enalapril group showed significant falls in blood pressure, heart rate, and concentrations of plasma angiotensin II, angiotensin converting enzyme, and noradrenaline. During the 12 week trial heart failure became worse in one enalapril treated patient (8%) and in seven placebo treated patients (58%). There were no significant changes in cardiac ejection fraction or exercise duration in either group. Plasma noradrenaline response to graded exercise and maximum exercise rate-pressure product were significantly reduced after four and 12 weeks of active treatment but unchanged with placebo treatment. There was a sustained increase in plasma potassium and a slight rise in plasma creatinine in the enalapril group. Plasma concentrations of the active drug, enalaprilate, were dose related and log enalaprilate correlated significantly with percentage of plasma angiotensin converting enzyme activity (r = -0.66). Enalapril was well tolerated and produced no adverse effects. The drug appears to be superior to placebo and offers considerable promise for the treatment of this condition.

Angiotensin II↗
PubMed1985

Hyperparathyroid bone disease in chronic renal failure.

Much has been learnt over the past 80 years of the pathogenesis and management of hyperparathyroid bone disease in uraemia. Clinically it has changed from a rare disorder of childhood and adolescence to a common and difficult problem in patients maintained on dialysis programmes. Whereas effective treatments are now available for hyperparathyroid bone disease, these are not curative and there is clearly much more work to be done before a full understanding of its pathogenesis, and the best methods of treatment and prevention, can be reached.

Bone Diseases↗
PubMed1984

Low-dose colestipol plus probucol for hypercholesterolemia.

The hypocholesterolemic and adverse effects of colestipol, 20 g/day, and colestipol, 10 g/day combined with probucol, 1 g/day, were compared. A double-placebo, diet-controlled, crossover trial that lasted 19 months was undertaken on 22 hypercholesterolemic patients who had low-density lipoprotein (LDL) cholesterol levels greater than 180 mg/dl after 3 months of diet and placebo treatment. Uniformity of diet and physical activity were monitored throughout the study. Compared with baseline values after 3 months on diet-placebo treatment, "combined" therapy reduced LDL cholesterol by more than 20% in 15 patients, more than 25% in 9 patients and more than 45% in 2 patients. Treatment with "half-dose" colestipol and probucol resulted in the greatest mean LDL cholesterol reduction, from 239 mg/dl during diet-placebo period to 170 mg/dl; the difference was not statistically significantly different from the reduction to 180 mg/dl with 20 g of colestipol alone. Fifteen patients showed the greatest reduction in LDL cholesterol after combined therapy. Probucol produced statistically significant reductions in very low density lipoprotein and high-density lipoprotein cholesterol. The major gastrointestinal side effects of single therapy with colestipol (constipation) and probucol (diarrhea) were ameliorated or abolished by concomitant administration. Probucol-colestipol co-administration allowed a 50% reduction in the colestipol dosage, with similar efficacy and improved tolerability and reduced mean serum LDL cholesterol with a frequency and magnitude rarely seen with other hypocholesterolemic treatments. Hypercholesterolemic persons who cannot tolerate full doses of resins may receive equal benefit by half the dose if probucol is added to the regimen.

Adult↗